Nic-induced NCLL could be inhibited by Baf. (A) FIP200KO-MEFs were treated with Nic (10 μM) in the presence or absence of Baf (0.5 μM), concanamycin (ConA) (1 μM), chloroquine (CQ) (40 μM), or ammonia chloride (AC) (20 mM) for 6 h, and then, the LC3-II formation was analyzed. (B) FIP200KO-MEFs were treated by Nic (10 μM) with or without Baf (0.5 μM) for 6 h, and then, the GFP-LC3 puncta formation was assessed. (C) WT-MEFs were treated by Nic (10 μM) with or without 3MA (10 mM) or Baf (0.5 μM) for 6 h, and then, the LC3-II formation was assessed. (D) WT-MEFs were treated with Nic (10 μM) in the presence or absence of Baf (0.5 μM) and/or 3MA (10 mM) for 6 h, and then, the GFP-LC3 puncta formation was assessed. (E,F) FIP200KO-MEFs were treated by Nic (10 μM) with or without Baf (0.5 μM) for 6 h, and then, the ATG16L1 (E) and ATG12 (F) puncta formations were assessed.CM, complete medium. Bar = 10 μM.